Meeting
2015 Gastrointestinal Cancers Symposium
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
Authors
Cathy Eng
The University of Texas MD Anderson Cancer Center, Houston, TX
Cathy Eng , Eric Van Cutsem , Elzbieta Nowara , Anna Swieboda-Sadlej , Niall C. Tebbutt , Edith P. Mitchell , Irina Davidenko , Oliver Lee , Kelly Smith Oliner , Marco Schupp , Elwyn Loh , Roger Sidhu , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00788957
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 694)
DOI
10.1200/jco.2015.33.3_suppl.694
Abstract #
694
Poster Bd #
D36
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
Poster
2016 ASCO Annual Meeting
A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.
First Author: Kohei Shitara
Poster
2014 ASCO Annual Meeting
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
First Author: Marc Peeters
Poster
2013 ASCO Annual Meeting
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
First Author: Lee Steven Schwartzberg